The Barts-MS team will attempt to declare all relevant conflicts of interest (CoI) in relation to each post. We realise the success of this blog depends on us being independent, or at least being transparent, and we will declare CoI on every relevant post.
Here are our general CoI.
We have received grant support from companies and organisations:
- The National Multiple Sclerosis Society
- The Multiple Sclerosis Society
- The Wellcome Trust
- The Medical Research Council
- Innovate UK
- And others, for which we are very grateful.
Professor Giovannoni and his group have received research grant support from Bayer-Schering Healthcare, Biogen-Idec, Genzyme, GW Pharma, Ironwood, Merck, Merck-Serono, Merz, Novartis, Teva and Sanofi-Aventis. He has received personal compensation for participating on advisory boards, trial steering committees and trial data and safety monitoring boards from: AbbVie, Atara Bio, Bayer-Schering Healthcare, Biogen, Canbex, Eisai, Elan, Fiveprime, Genzyme-Sanofi, Genentech, GSK, GW Pharma, Ironwood, Merck, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals.
MouseDoctor is founder/shareholder of a University Spinout Company, Canbex, aiming to develop new anti-symptomatic drugs for MS. He has provided ad-hoc consultancies and/or been the recipient of research grants/contracts from some of the companies mentioned above. He supports the concept of off label DMT use. He has received personal compensation from Sanofi Genzyme and Japanese Tobacco, Canbex Therapeutics.
MouseDoctor2 as an inventor is a shareholder in the University Spinout Company and has undertaken contract research testing for some of the companies mentioned above.
Klaus Schmierer (DrK) is a principal investigator of trials sponsored by Novartis, Roche and Teva. He is also involved in trials sponsored by Biogen, Genzyme, BIAL, has received speaking honoraria from, and/or served in an advisory role for, Biogen, Novartis, Teva, Merck, Merck Inc., and support to attend meetings from Genzyme and Novartis. DrK and his group have received research grant support from Novartis, the Wellcome Trust, the National MS Society (US), the MS Society of Great Britain & Northern Ireland, the Royal College of Radiologists, and Barts Charity.
NeuroDoc Gnanapavan has served in an advisory role for Novartis and received travel support from Teva and Novartis. She has received research grant support from the National MS Society (US).
General Disclaimer: Please note that the opinions expressed here are those of the individual bloggers and do not necessarily reflect the positions of the Barts and The London School of Medicine and Dentistry or Barts Health NHS Trust.
Survey Disclaimer: No personal identifiers will be collected as part of these surveys. By completing these surveys you are consenting to the data you provide being analysed by Professors Giovannoni and Baker and their collaborators. Results of these surveys will be presented on this blog and may be submitted for publication.